Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162982 | 0.98 | HPGD (0.55) | HPGDCYP4A11CYP4F2LMNAALDH1A1 | |
| SCHEMBL2162296 | 0.94 | HPGD (0.52) | HPGDCYP4A11CYP4F2LMNAALDH1A1 | |
| SCHEMBL7211528 | 0.88 | HPGD (0.57) | HPGDLMNAALDH1A1PRNPRECQL | |
| SCHEMBL1368290 | 0.87 | NPSR1 (0.50) | HPGDCYP4A11CYP4F2LMNAALDH1A1 | |
| SCHEMBL6978193 | 0.86 | HPGD (0.59) | HPGDCYP4A11CYP4F2LMNAALDH1A1 | |
| SCHEMBL27621806 | 0.86 | HPGD (0.55) | HPGDLMNAALDH1A1PRNPRECQL | |
| SCHEMBL2654064 | 0.85 | POLB (0.49) | HPGDCYP4A11CYP4F2LMNAALDH1A1 | |
| SCHEMBL2655129 | 0.85 | POLB (0.49) | HPGDCYP4A11CYP4F2LMNAALDH1A1 | |
| SCHEMBL2653395 | 0.85 | POLB (0.49) | HPGDCYP4A11CYP4F2LMNAALDH1A1 | |
| SCHEMBL2160349 | 0.84 | HPGD (0.54) | HPGDLMNAALDH1A1PRNPRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303251-A1 | CONJUGATES OF GARFTASE INHIBITORS | ENDOCYTE, INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016089879-A1 | CONJUGATES OF GARFTASE INHIBITORS | ENDOCYTE, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-1109560-B1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6525050-B1 | Inhibit the enzyme aminoimidazole carboxamide ribonucleotide formyl transferase; antiproliferative agents; antitumor, antiinflammatory, antipsoriatic, and/or immunosuppressive | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1109560-A4 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMA (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1109560-A1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000013688-A1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303251-A1 | CONJUGATES OF GARFTASE INHIBITORS | DHFR, FOLR1, MTHFD1 | HPGD 1936/4885CYP4A11 3372/4885CYP4F2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.